Baptist Cancer Services offers patients participation in clinical trials. Following are the clinical trials currently available. For more information, contact our Baptist Cancer Services Navigator, Tonya Ball, at 601-974-6238. (Updated 3/18/2016)
Puma Biotechnology - Neratinib plus Xeloda versus Tykerb plus Xeloda in patients with HER 2 positive metastatic breast cancer who have received two or more regimens for metastatic disease
Genentech - Atezolizumab in combination with Abraxane vs. Placebo with Abraxane for patients with previously untreated Metastatic triple negative breast cancer. The Abraxane, Placeob, and Atezolizumab are provided by Genentech
Tesaro - Phase 3 randomized trial of Niraparib vs. physician choice chemotherapy in previously treated, HER2 negative, germline BRACA mutation-positive breast cancer patients
Pharmacyclics -Observational registry of CLL patients designed to describe treatment patterns and assess patient's quality of life
Astellas - Randomized phase 3 study of ASP8273 vs. Erlotinib in first- line treatment of advanced NSCLC with EGFR mutations
BMS - Nivolumab in advanced NSCLC as maintenance after induction chemotherapy or as first line treatment with standard of care regimens
Inivata - Prospective observation multicenter study to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced non small cell lung cancer
Duke Registry - a registry of non small cell lung cancer patients to collect information regarding treatments, response and quality of life surveys; patients complete a survey every three months
Baptist has partnered with Conversant Bio to participate in an observational study. Conversant Bio’s work involves using biospecimens obtained during scheduled procedures. These biospecimens include blood taken at the same time blood is drawn for physician ordered tests and/or unused tissue from a surgical procedure that is not needed for diagnosis or treatment. The biospecimens obtained are sent to researchers who work with all disease types. Participation may assist these researchers in developing new treatments or improving procedures for detecting diseases. There is no increased risk to participate and participation is strictly voluntary.
What can we help you find?